Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factor VIII - Takeda

Drug Profile

Factor VIII - Takeda

Alternative Names: Factor VIII autologous cell therapy - Takeda; Factor VIII autologous cell therapy - Transkaryotic Therapies; Factor VIII cell therapy - Takeda; Factor VIII cell therapy - Transkaryotic Therapies; Factor VIII replacement therapy - Takeda; FVIII therapy - Takeda

Latest Information Update: 15 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Rani Therapeutics; Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Haemophilia A

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 06 Dec 2017 Early research in Haemophilia A in Ireland (PO)
  • 05 Dec 2017 Shire and Rani Therapeutics agree to evaluate the use of the Rani Pill™ technology for oral delivery of factor VIII therapy for haemophilia A
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top